Biodel Inc  

(Public, NASDAQ:BIOD)   Watch this stock  
Find more results for BIOD
1.90
-0.06 (-3.06%)
Jul 31 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 1.89 - 1.97
52 week 1.85 - 6.08
Open 1.97
Vol / Avg. 0.00/202,681.00
Mkt cap 40.12M
P/E     -
Div/yield     -
EPS -1.11
Shares 21.12M
Beta 1.89
Inst. own 24%
Aug 13, 2014
Biodel Inc at Wedbush Securities Life Sciences Conference - 12:45PM EDT - Add to calendar
Aug 11, 2014
Q3 2014 BIODEL INC Earnings Release (Estimated) Add to calendar
Jun 25, 2014
Biodel Inc at JMP Securities Healthcare Conference
May 13, 2014
Q2 2014 BIODEL INC Earnings Conference Call
May 13, 2014
Q2 2014 BIODEL INC Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '14) 2013
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -73.88% -47.00%
Return on average equity -90.60% -60.89%
Employees 36 -
CDP Score - -

Address

100 Saw Mill Road
DANBURY, CT 06810
United States - Map
+1-203-7965000 (Phone)
+1-203-7965001 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Biodel Inc. (Biodel) is a development-stage specialty biopharmaceutical company focused on the development and commercialization of treatments for diabetes. The Company develops its product candidates by applying its formulation technologies to existing drugs. Its insulin formulations are designed to be rapid-acting than the formulations are available to Type 1 and Type 2 diabetes patients. It refers to these as ultra-rapid-acting formulations. The clinical trial was a single center, randomized, double-blind, three-period crossover trial in 12 patients with Type 1 diabetes. The Company has conducted Phase 1, Phase 2 and Phase 3 clinical trials comparing the performance of its Linjeta formulation of RHI to either Humulin R, which is a branded formulation of RHI, or Humalog. Its pivotal Phase III clinical trials were open-label, parallel group, randomized trials conducted at centers in the United States, Germany and India.

Officers and directors

Ira W. Lieberman Ph.D. Independent Chairman of the Board
Age: 71
Bio & Compensation  - Reuters
Errol B. De Souza Ph.D. President, Chief Executive Officer, Principal Financial Officer, Director
Age: 60
Bio & Compensation  - Reuters
Paul S. Bavier Chief Compliance Officer, General Counsel, Secretary
Age: 41
Bio & Compensation  - Reuters
Erik Steiner Vice President - Operations
Age: 48
Bio & Compensation  - Reuters
Alan Seth Krasner M.D. Chief Medical Officer
Age: 50
Bio & Compensation  - Reuters
Davey S. Scoon CPA Director
Age: 67
Bio & Compensation  - Reuters
Julia R. Brown Independent Director
Age: 66
Bio & Compensation  - Reuters
Barry H. Ginsberg M.D., Ph.D. Independent Director
Age: 68
Bio & Compensation  - Reuters
Daniel Lorber M.D. Independent Director
Age: 67
Bio & Compensation  - Reuters
Brian J. G. Pereira M.D. Independent Director
Age: 55
Bio & Compensation  - Reuters